% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Biel:281802,
      author       = {Biel, Davina and Steward, Anna and Dewenter, Anna and
                      Dehsarvi, Amir and Zhu, Zeyu and Roemer-Cassiano, Sebastian
                      N and Frontzkowski, Lukas and Hirsch, Fabian and Palleis,
                      Carla and Höglinger, Günter and Brendel, Matthias and
                      Franzmeier, Nicolai},
      title        = {{A} systematic comparison of {ATN} biomarkers for
                      monitoring longitudinal cognitive changes in {A}lzheimer's
                      disease},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {10},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-01188},
      pages        = {e70783},
      year         = {2025},
      abstract     = {INTRODUCTIONWith anti-amyloid beta (Aβ) therapies approved
                      for Alzheimer's disease (AD), surrogate biomarkers are
                      needed to monitor clinical treatment efficacy. Therefore, we
                      systematically compared longitudinal changes in A/T/N
                      biomarkers (amyloid-positron emission tomography [PET],
                      tau-PET, plasma phosphorylated tau at threonine 217
                      [p-tau217], and magnetic resonance imaging) for tracking
                      cognitive changes.METHODSWe analyzed longitudinal biomarker
                      and cognitive change rates from the Alzheimer's Disease
                      Neuroimaging Initiative (N = 141) and Anti-Amyloid Treatment
                      in Asymptomatic Alzheimer's (A4) and Longitudinal Evaluation
                      of Amyloid Risk and Neurodegeneration (LEARN) (N = 151),
                      estimated using linear mixed models. Using linear models, we
                      tested biomarker changes as predictors of cognitive changes,
                      comparing predictive strengths across biomarkers using
                      bootstrapping.RESULTSTau-PET, plasma p-tau217, and cortical
                      thickness changes accurately tracked change rates in
                      Mini-Mental State Examination, Alzheimer's Disease
                      Assessment Scale-Cognitive Subscale 13-item version,
                      Clinical Dementia Rating-Sum of Boxes, and Preclinial
                      Alzheimer Cognitive Composite scores. In contrast,
                      amyloid-PET change rates were not linked to cognitive
                      changes.DISCUSSIONPlasma p-tau217 offers a cost-effective
                      AD-specific alternative to tau-PET and could potentially be
                      implemented for monitoring cognitive changes in AD trials,
                      while amyloid-PET lacks utility. Cortical thickness changes
                      accurately track cognitive changes but may be confounded by
                      pseudo-atrophy in anti-Aβ treatments.},
      cin          = {Clinical Research (Munich) / AG Haass},
      ddc          = {610},
      cid          = {I:(DE-2719)1111015 / I:(DE-2719)1110007},
      pnm          = {353 - Clinical and Health Care Research (POF4-353) / 352 -
                      Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1002/alz.70783},
      url          = {https://pub.dzne.de/record/281802},
}